| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$13 |
Application for quotation of securities - TRU
|
28 Jul 2025 10:43AM |
$0.016 |
$0.017 |
risen by
6.25%
|
|
| Lycopodium Limited (LYL) ORDINARY FULLY PAID |
Industrials |
$467 |
FY2025 Results Notification & Webinar
|
28 Jul 2025 10:41AM |
$11.680 |
$11.760 |
risen by
0.68%
|
|
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$13 |
Corporate Action Notice
|
28 Jul 2025 10:41AM |
$0.016 |
$0.017 |
risen by
6.25%
|
|
TRU - Price-sensitive ASX Announcement
Full Release
Key Points
- Truscreen Group Limited is announcing a pro rata non-renounceable rights issue to shareholders.
- Eligible shareholders can subscribe for 1 new share for every 5.4 shares held.
- The issue price is NZ$0.035 per new share.
- The company aims to raise approximately NZ$2.6 million before costs.
- Funds will be used for product development, commercialization, and working capital.
- The rights issue is partially underwritten.
- Key offer dates, including ex-date, record date, and offer closing, are specified in the notice.
- New shares will carry the same rights and obligations as existing shares.
- Eligibility is limited to shareholders in New Zealand and Australia as at the record date.
- The announcement fulfills disclosure requirements under NZX and ASX Listing Rules.
- No shareholder approval or prospectus is required for this rights issue.
- Director participation and underwriting arrangements are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anatara Lifesciences Ltd (ANR) ORDINARY FULLY PAID |
Health Care |
$1 |
Anatara receives $969,455 in R&D Tax Incentive for FY25
|
28 Jul 2025 10:40AM |
$0.008 |
$0.007 |
fallen by
12.50%
|
|
ANR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anatara Lifesciences Ltd received $969,455 in R&D Tax Incentive funding for FY25.
- The funding comes from the Australian Federal Government’s R&D Tax Incentive program.
- Funds will support research and development efforts in both human and animal health portfolios.
- Projects supported include the GaRP human gastrointestinal health product and Detach® for animal health.
- The company is advancing its clinical and preclinical trial programs.
- The R&D Tax Incentive provides significant non-dilutive funding to Anatara.
- This funding will be used to progress product development and commercialization efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$387 |
MA1 July 2025 Estimate Distribution Announcement
|
28 Jul 2025 10:36AM |
$2.050 |
$2.030 |
fallen by
0.98%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$125 |
Investor Presentation
|
28 Jul 2025 10:36AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$381 |
TItomic Establishes UK Subsidiary
|
28 Jul 2025 10:33AM |
$0.285 |
$0.250 |
fallen by
12.28%
|
|
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$22 |
Cleansing notice - Exercise of $0.10c Options
|
28 Jul 2025 10:33AM |
$0.130 |
$0.105 |
fallen by
19.23%
|
|
| Saturn Metals Limited (STN) ORDINARY FULLY PAID |
Materials |
$189 |
Trading Halt
|
28 Jul 2025 10:32AM |
$0.415 |
$0.410 |
fallen by
1.20%
|
|
STN - Price-sensitive ASX Announcement
Full Release
Key Points
- Saturn Metals Limited requested a trading halt on 28 September 2023.
- The trading halt is due to a pending announcement regarding a material capital raising.
- The halt will last until the earlier of a further announcement or the start of trading on 2 October 2023.
- The company states the halt is necessary to ensure an informed market and fair trading.
- No further details about the capital raising are disclosed in the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spartan Resources Limited (SPR) ORDINARY FULLY PAID |
Materials |
$2,847 |
Change in substantial holding for BNZ
|
28 Jul 2025 10:32AM |
$2.130 |
$2.130 |
fallen by
0%
|
|
| Benz Mining Corp (BNZ) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$167 |
Change in substantial holding from SPR
|
28 Jul 2025 10:32AM |
$0.590 |
$0.985 |
risen by
66.95%
|
|
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$22 |
Application for quotation of securities - AR3
|
28 Jul 2025 10:29AM |
$0.130 |
$0.105 |
fallen by
19.23%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$125 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jul 2025 10:29AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers the period ending 31 March 2024.
- Arovella continued development of its ALA-101 and ALA-104 cell therapy programs targeting blood cancers.
- Progress made in manufacturing and preclinical development of ALA-101, including collaboration with clinical and manufacturing partners.
- ALA-104 program advanced with further research and development activities.
- New collaborations and licensing agreements established to expand the company's pipeline and capabilities.
- Ongoing regulatory and quality assurance activities to support progression toward clinical trials.
- Report includes Appendix 4C Cash Flow statement, outlining receipts from customers, research and development outflows, and overall financial position.
- Company maintains focus on capital management to fund its research and operational activities.
- No significant changes in business activities or control over entities during the quarter.
- The company is actively seeking additional funding sources to support continued operations and growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Jul 2025 10:28AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| NuEnergy Gas Limited (NGY) ORDINARY FULLY PAID |
Energy |
$62 |
Commenced spudding of third well - TE-B-6--3
|
28 Jul 2025 10:26AM |
$0.035 |
$0.035 |
fallen by
0%
|
|
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Continuation of Suspension from Quotation
|
28 Jul 2025 10:23AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$147 |
CEO Appointment Joe Coote
|
28 Jul 2025 10:22AM |
$0.180 |
$0.165 |
fallen by
8.33%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Joe Coote appointed as CEO of Bubs Australia Limited
- Coote has significant experience in the dairy and infant nutrition sectors
- The board emphasizes confidence in Coote’s ability to drive growth
- Strategic priorities include expansion and profitability improvement
- Joe Coote’s previous roles include leadership positions at major industry companies
- Appointment aligns with Bubs’ commitment to strengthen its market position
- The board welcomes Joe Coote and anticipates positive impact on company direction
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brightstar Resources Limited (BTR) ORDINARY FULLY PAID |
Materials |
$249 |
Security Holder Support Received for BTR
|
28 Jul 2025 10:18AM |
$0.480 |
$0.430 |
fallen by
10.42%
|
|
| Aurumin Limited (AUN) ORDINARY FULLY PAID |
Materials |
$50 |
Security Holder Support Received for BTR
|
28 Jul 2025 10:18AM |
$0.110 |
$0.100 |
fallen by
9.09%
|
|
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$387 |
Dividend/Distribution - MA1
|
28 Jul 2025 10:17AM |
$2.040 |
$2.030 |
fallen by
0.49%
|
|
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$7 |
Change of Director's Interest Notice on Consolidation x 3
|
28 Jul 2025 10:16AM |
$0.100 |
$0.059 |
fallen by
41%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$3 |
Quarterly Activities Report and Appendix 5B
|
28 Jul 2025 10:11AM |
$0.001 |
$0.002 |
risen by
50%
|
|
MOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report and Appendix 5B released for period ending 31 December 2023.
- Ongoing exploration and target generation at the Woodlands Project, Western Australia.
- Further geological mapping and soil sampling conducted.
- Assessment of lithium and critical minerals prospects continued.
- Appointment of new Managing Director announced.
- Appendix 5B summarises company’s cash flows, focusing on exploration and evaluation outflows.
- Company maintains stable financial position with adequate cash reserves.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventus Medical, Inc. (VNT2) ORDINARY FULLY PAID |
- |
- |
Webcast and Conference Call details for HY25 Results
|
28 Jul 2025 10:10AM |
n/a |
n/a |
n/a
|
|
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$11 |
Reinstatement to Quotation
|
28 Jul 2025 10:10AM |
$0.072 |
$0.058 |
fallen by
19.44%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) has been reinstated to quotation on the ASX.
- The company operates graphite mining and processing projects in Western Australia.
- Reinstatement follows compliance with ASX listing rules and completion of capital raising.
- Funds raised will be used for project development, working capital, and exploration.
- Updates are provided on the Springdale Graphite Project and Collie downstream processing facility.
- The company remains committed to progressing its graphite business strategy.
- Board and management changes are detailed as part of ongoing corporate development.
- Recent financial activities and share structure updates are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$11 |
Agreement to develop new Expandable Graphite facility
|
28 Jul 2025 10:09AM |
$0.072 |
$0.058 |
fallen by
19.44%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) and a Chinese industrial group have entered a non-binding agreement.
- The agreement is to develop and construct a new expandable graphite facility in Collie, Western Australia.
- Graphite feedstock will be sourced from IG6’s Springdale Graphite Project and processed at the Collie facility.
- The Chinese partner will contribute technology, design, and market access.
- The agreement supports IG6’s strategy to establish an integrated Australian graphite supply chain.
- Expandable graphite is a value-added product used in batteries and flame retardant applications.
- The partnership accelerates IG6’s timeline for entering the expandable graphite market.
- The facility aims to serve both domestic and international markets.
- The agreement remains subject to due diligence, definitive documentation, and regulatory approvals.
- Project supports Western Australia’s ambitions in critical minerals processing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
